Effect of intravenous dopamine infusion on plasma concentrations of dopamine and dopamine sulfate in men, during and up to 18 ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2000-01

AUTHORS

A. Onasch, A. Tanzeem, F. Isgro, D. Böning, G. Strobel

ABSTRACT

Objective: We investigated whether sulfoconjugation contributes to the inactivation of intravenously infused dopamine (DA) in low concentrations with a predominant action on the kidney.Methods: Plasma DA and dopamine sulfate (DA-S) concentrations were determined during 4 h of intravenous infusion of DA (2 μg/kg/min) and up to 18 h after cessation of infusion. Twenty-seven healthy young subjects participated in the placebo controlled, randomised and double-blind study.Results: Intravenously administered DA was sulfoconjugated rapidly and to a great extent. After starting the infusion, DA levels rose within minutes and reached a steady state after 30–60 min. The steady-state levels averaged 151.3 ± 8.2 nmol/l. DA-S levels also increased markedly with infusion from 16.7 ± 9.9 nmol/l at the start of infusion up to 261.2 ± 24.2 nmol/l at 30 min after cessation of infusion. Plasma DA concentrations after cessation of the infusion decreased rapidly with an initial half-life of elimination of 4.8 min. Concentrations of plasma DA-S declined with a half-life of 4.5 h. Persistent elevations of free and conjugated DA compared with pre-treatment levels were observed even 18 h after cessation. Heart rate and blood pressure remained unchanged both during DA and saline infusion.Conclusion: Findings indicate that the sulfoconjugation pathway contributes markedly to the inactivation of intravenously infused DA and seems not to be saturable by DA infusion in low doses. More... »

PAGES

755-759

References to SciGraph publications

  • 1979-10. Nonlinear least-squares regression programs for microcomputers in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 1984-03. Correlation between the pharmacokinetics and pharmacodynamics of dopamine in healthy subjects in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s002280050010

    DOI

    http://dx.doi.org/10.1007/s002280050010

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1028410726

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/10663455


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adult", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Blood Pressure", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dopamine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Heart Rate", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Infusions, Intravenous", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Male", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Sulfuric Acid Esters", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Time Factors", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Institute of Sports Medicine, Universit\u00e4tsklinikum Benjamin Franklin, Free University Berlin, Clayallee 229, D-14195 Berlin, Germany e-mail: gstrobel@zedat.fu-berlin.de Tel.: +49-30-81812573; Fax: +49-30-81812572, DE", 
              "id": "http://www.grid.ac/institutes/grid.14095.39", 
              "name": [
                "Institute of Sports Medicine, Universit\u00e4tsklinikum Benjamin Franklin, Free University Berlin, Clayallee 229, D-14195 Berlin, Germany e-mail: gstrobel@zedat.fu-berlin.de Tel.: +49-30-81812573; Fax: +49-30-81812572, DE"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Onasch", 
            "givenName": "A.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Institute of Heart Surgery, Ruprecht Karls University, Heidelberg, Germany, DE", 
              "id": "http://www.grid.ac/institutes/grid.7700.0", 
              "name": [
                "Institute of Heart Surgery, Ruprecht Karls University, Heidelberg, Germany, DE"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tanzeem", 
            "givenName": "A.", 
            "id": "sg:person.01062437511.52", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062437511.52"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Institute of Heart Surgery, Ludwigshafen, Germany, DE", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "Institute of Heart Surgery, Ludwigshafen, Germany, DE"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Isgro", 
            "givenName": "F.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Institute of Sports Medicine, Universit\u00e4tsklinikum Benjamin Franklin, Free University Berlin, Clayallee 229, D-14195 Berlin, Germany e-mail: gstrobel@zedat.fu-berlin.de Tel.: +49-30-81812573; Fax: +49-30-81812572, DE", 
              "id": "http://www.grid.ac/institutes/grid.14095.39", 
              "name": [
                "Institute of Sports Medicine, Universit\u00e4tsklinikum Benjamin Franklin, Free University Berlin, Clayallee 229, D-14195 Berlin, Germany e-mail: gstrobel@zedat.fu-berlin.de Tel.: +49-30-81812573; Fax: +49-30-81812572, DE"
              ], 
              "type": "Organization"
            }, 
            "familyName": "B\u00f6ning", 
            "givenName": "D.", 
            "id": "sg:person.0773653551.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773653551.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Institute of Sports Medicine, Universit\u00e4tsklinikum Benjamin Franklin, Free University Berlin, Clayallee 229, D-14195 Berlin, Germany e-mail: gstrobel@zedat.fu-berlin.de Tel.: +49-30-81812573; Fax: +49-30-81812572, DE", 
              "id": "http://www.grid.ac/institutes/grid.14095.39", 
              "name": [
                "Institute of Sports Medicine, Universit\u00e4tsklinikum Benjamin Franklin, Free University Berlin, Clayallee 229, D-14195 Berlin, Germany e-mail: gstrobel@zedat.fu-berlin.de Tel.: +49-30-81812573; Fax: +49-30-81812572, DE"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Strobel", 
            "givenName": "G.", 
            "id": "sg:person.01013473131.82", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013473131.82"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1007/bf01062394", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1025280421", 
              "https://doi.org/10.1007/bf01062394"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00630281", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007891280", 
              "https://doi.org/10.1007/bf00630281"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2000-01", 
        "datePublishedReg": "2000-01-01", 
        "description": "Objective: We investigated whether sulfoconjugation contributes to the inactivation of intravenously infused dopamine (DA) in low concentrations with a predominant action on the kidney.Methods: Plasma DA and dopamine sulfate (DA-S) concentrations were determined during 4\u2009h of intravenous infusion of DA (2\u2009\u03bcg/kg/min) and up to 18\u2009h after cessation of infusion. Twenty-seven healthy young subjects participated in the placebo controlled, randomised and double-blind study.Results: Intravenously administered DA was sulfoconjugated rapidly and to a great extent. After starting the infusion, DA levels rose within minutes and reached a steady state after 30\u201360\u2009min. The steady-state levels averaged 151.3\u2009\u00b1\u20098.2\u2009nmol/l. DA-S levels also increased markedly with infusion from 16.7\u2009\u00b1\u20099.9\u2009nmol/l at the start of infusion up to 261.2\u2009\u00b1\u200924.2\u2009nmol/l at 30\u2009min after cessation of infusion. Plasma DA concentrations after cessation of the infusion decreased rapidly with an initial half-life of elimination of 4.8\u2009min. Concentrations of plasma DA-S declined with a half-life of 4.5\u2009h. Persistent elevations of free and conjugated DA compared with pre-treatment levels were observed even 18\u2009h after cessation. Heart rate and blood pressure remained unchanged both during DA and saline infusion.Conclusion: Findings indicate that the sulfoconjugation pathway contributes markedly to the inactivation of intravenously infused DA and seems not to be saturable by DA infusion in low doses.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s002280050010", 
        "inLanguage": "en", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1054337", 
            "issn": [
              "0031-6970", 
              "1432-1041"
            ], 
            "name": "European Journal of Clinical Pharmacology", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "10", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "55"
          }
        ], 
        "keywords": [
          "cessation of infusion", 
          "plasma dopamine", 
          "plasma DA concentrations", 
          "double-blind study", 
          "intravenous dopamine infusion", 
          "start of infusion", 
          "healthy young subjects", 
          "pre-treatment levels", 
          "DA infusion", 
          "dopamine infusion", 
          "blood pressure", 
          "persistent elevation", 
          "intravenous infusion", 
          "DA levels", 
          "conjugated dopamine", 
          "dopamine sulfate", 
          "saline infusion", 
          "plasma concentrations", 
          "heart rate", 
          "young subjects", 
          "infusion", 
          "low doses", 
          "dopamine", 
          "DA concentration", 
          "predominant action", 
          "cessation", 
          "steady-state levels", 
          "min", 
          "placebo", 
          "levels", 
          "kidney", 
          "doses", 
          "low concentrations", 
          "greater extent", 
          "men", 
          "inactivation", 
          "concentration", 
          "subjects", 
          "elevation", 
          "minutes", 
          "findings", 
          "pathway", 
          "contributes", 
          "elimination", 
          "study", 
          "start", 
          "action", 
          "rate", 
          "effect", 
          "pressure", 
          "extent", 
          "sulfate", 
          "steady state", 
          "state", 
          "sulfate concentrations"
        ], 
        "name": "Effect of intravenous dopamine infusion on plasma concentrations of dopamine and dopamine sulfate in men, during and up to 18 h after infusion", 
        "pagination": "755-759", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1028410726"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s002280050010"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "10663455"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s002280050010", 
          "https://app.dimensions.ai/details/publication/pub.1028410726"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-06-01T22:03", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_310.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s002280050010"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s002280050010'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s002280050010'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s002280050010'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s002280050010'


     

    This table displays all metadata directly associated to this object as RDF triples.

    193 TRIPLES      22 PREDICATES      93 URIs      83 LITERALS      16 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s002280050010 schema:about N08acd75e73c242bd9c522685e5f5251a
    2 N970c5be0250344e28fa3bae22e0b039c
    3 Na2c60dfc289c4c76a722cb34197c4133
    4 Nac5e2ebeed554a63985d449cf6c7b376
    5 Nbb08844bf721408cacae409d355b75d4
    6 Nda24ec3ac6d24041a84e35129a9f83a8
    7 Nf0cc324f2a1c4f00ab3869bb740ea257
    8 Nf40d2da123ac4e6a838bea704a92f9b1
    9 Nf8000f34f1534297913146e1c851a1a8
    10 anzsrc-for:11
    11 anzsrc-for:1103
    12 schema:author N3dffca43427f4623a864ddedd2118e56
    13 schema:citation sg:pub.10.1007/bf00630281
    14 sg:pub.10.1007/bf01062394
    15 schema:datePublished 2000-01
    16 schema:datePublishedReg 2000-01-01
    17 schema:description Objective: We investigated whether sulfoconjugation contributes to the inactivation of intravenously infused dopamine (DA) in low concentrations with a predominant action on the kidney.Methods: Plasma DA and dopamine sulfate (DA-S) concentrations were determined during 4 h of intravenous infusion of DA (2 μg/kg/min) and up to 18 h after cessation of infusion. Twenty-seven healthy young subjects participated in the placebo controlled, randomised and double-blind study.Results: Intravenously administered DA was sulfoconjugated rapidly and to a great extent. After starting the infusion, DA levels rose within minutes and reached a steady state after 30–60 min. The steady-state levels averaged 151.3 ± 8.2 nmol/l. DA-S levels also increased markedly with infusion from 16.7 ± 9.9 nmol/l at the start of infusion up to 261.2 ± 24.2 nmol/l at 30 min after cessation of infusion. Plasma DA concentrations after cessation of the infusion decreased rapidly with an initial half-life of elimination of 4.8 min. Concentrations of plasma DA-S declined with a half-life of 4.5 h. Persistent elevations of free and conjugated DA compared with pre-treatment levels were observed even 18 h after cessation. Heart rate and blood pressure remained unchanged both during DA and saline infusion.Conclusion: Findings indicate that the sulfoconjugation pathway contributes markedly to the inactivation of intravenously infused DA and seems not to be saturable by DA infusion in low doses.
    18 schema:genre article
    19 schema:inLanguage en
    20 schema:isAccessibleForFree false
    21 schema:isPartOf N6bc5b9e8cab440058623743795c34641
    22 N8a113064184b47d886b4cd1509a1f010
    23 sg:journal.1054337
    24 schema:keywords DA concentration
    25 DA infusion
    26 DA levels
    27 action
    28 blood pressure
    29 cessation
    30 cessation of infusion
    31 concentration
    32 conjugated dopamine
    33 contributes
    34 dopamine
    35 dopamine infusion
    36 dopamine sulfate
    37 doses
    38 double-blind study
    39 effect
    40 elevation
    41 elimination
    42 extent
    43 findings
    44 greater extent
    45 healthy young subjects
    46 heart rate
    47 inactivation
    48 infusion
    49 intravenous dopamine infusion
    50 intravenous infusion
    51 kidney
    52 levels
    53 low concentrations
    54 low doses
    55 men
    56 min
    57 minutes
    58 pathway
    59 persistent elevation
    60 placebo
    61 plasma DA concentrations
    62 plasma concentrations
    63 plasma dopamine
    64 pre-treatment levels
    65 predominant action
    66 pressure
    67 rate
    68 saline infusion
    69 start
    70 start of infusion
    71 state
    72 steady state
    73 steady-state levels
    74 study
    75 subjects
    76 sulfate
    77 sulfate concentrations
    78 young subjects
    79 schema:name Effect of intravenous dopamine infusion on plasma concentrations of dopamine and dopamine sulfate in men, during and up to 18 h after infusion
    80 schema:pagination 755-759
    81 schema:productId N841ae42825c44611aa786ef776549d1f
    82 Na9992fdeb3e048569ee693f58171849e
    83 Nfed1d1453507416a8da0c3e9011b2107
    84 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028410726
    85 https://doi.org/10.1007/s002280050010
    86 schema:sdDatePublished 2022-06-01T22:03
    87 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    88 schema:sdPublisher N1bee915e5015403591618e8f12ddadc1
    89 schema:url https://doi.org/10.1007/s002280050010
    90 sgo:license sg:explorer/license/
    91 sgo:sdDataset articles
    92 rdf:type schema:ScholarlyArticle
    93 N08acd75e73c242bd9c522685e5f5251a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    94 schema:name Heart Rate
    95 rdf:type schema:DefinedTerm
    96 N168976e8fb264d0996f9ee96faa07aa1 rdf:first sg:person.01013473131.82
    97 rdf:rest rdf:nil
    98 N1bee915e5015403591618e8f12ddadc1 schema:name Springer Nature - SN SciGraph project
    99 rdf:type schema:Organization
    100 N30681f4d75264a489163913971266e56 rdf:first sg:person.01062437511.52
    101 rdf:rest Na62c80e37eb24b73aeaa8322a3f8ba7d
    102 N3dffca43427f4623a864ddedd2118e56 rdf:first Ne1412800f7a9409bab1e771beb6727bf
    103 rdf:rest N30681f4d75264a489163913971266e56
    104 N612d98903b414b318fe8b870498247b0 rdf:first sg:person.0773653551.22
    105 rdf:rest N168976e8fb264d0996f9ee96faa07aa1
    106 N6bc5b9e8cab440058623743795c34641 schema:volumeNumber 55
    107 rdf:type schema:PublicationVolume
    108 N841ae42825c44611aa786ef776549d1f schema:name dimensions_id
    109 schema:value pub.1028410726
    110 rdf:type schema:PropertyValue
    111 N8a113064184b47d886b4cd1509a1f010 schema:issueNumber 10
    112 rdf:type schema:PublicationIssue
    113 N970c5be0250344e28fa3bae22e0b039c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    114 schema:name Sulfuric Acid Esters
    115 rdf:type schema:DefinedTerm
    116 Na2c60dfc289c4c76a722cb34197c4133 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    117 schema:name Infusions, Intravenous
    118 rdf:type schema:DefinedTerm
    119 Na62c80e37eb24b73aeaa8322a3f8ba7d rdf:first Ne6bf23e66eac4a1a96fee187c10bec1d
    120 rdf:rest N612d98903b414b318fe8b870498247b0
    121 Na9992fdeb3e048569ee693f58171849e schema:name doi
    122 schema:value 10.1007/s002280050010
    123 rdf:type schema:PropertyValue
    124 Nac5e2ebeed554a63985d449cf6c7b376 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    125 schema:name Dopamine
    126 rdf:type schema:DefinedTerm
    127 Nbb08844bf721408cacae409d355b75d4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    128 schema:name Adult
    129 rdf:type schema:DefinedTerm
    130 Nda24ec3ac6d24041a84e35129a9f83a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    131 schema:name Time Factors
    132 rdf:type schema:DefinedTerm
    133 Ne1412800f7a9409bab1e771beb6727bf schema:affiliation grid-institutes:grid.14095.39
    134 schema:familyName Onasch
    135 schema:givenName A.
    136 rdf:type schema:Person
    137 Ne6bf23e66eac4a1a96fee187c10bec1d schema:affiliation grid-institutes:None
    138 schema:familyName Isgro
    139 schema:givenName F.
    140 rdf:type schema:Person
    141 Nf0cc324f2a1c4f00ab3869bb740ea257 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    142 schema:name Humans
    143 rdf:type schema:DefinedTerm
    144 Nf40d2da123ac4e6a838bea704a92f9b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    145 schema:name Blood Pressure
    146 rdf:type schema:DefinedTerm
    147 Nf8000f34f1534297913146e1c851a1a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Male
    149 rdf:type schema:DefinedTerm
    150 Nfed1d1453507416a8da0c3e9011b2107 schema:name pubmed_id
    151 schema:value 10663455
    152 rdf:type schema:PropertyValue
    153 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    154 schema:name Medical and Health Sciences
    155 rdf:type schema:DefinedTerm
    156 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    157 schema:name Clinical Sciences
    158 rdf:type schema:DefinedTerm
    159 sg:journal.1054337 schema:issn 0031-6970
    160 1432-1041
    161 schema:name European Journal of Clinical Pharmacology
    162 schema:publisher Springer Nature
    163 rdf:type schema:Periodical
    164 sg:person.01013473131.82 schema:affiliation grid-institutes:grid.14095.39
    165 schema:familyName Strobel
    166 schema:givenName G.
    167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013473131.82
    168 rdf:type schema:Person
    169 sg:person.01062437511.52 schema:affiliation grid-institutes:grid.7700.0
    170 schema:familyName Tanzeem
    171 schema:givenName A.
    172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062437511.52
    173 rdf:type schema:Person
    174 sg:person.0773653551.22 schema:affiliation grid-institutes:grid.14095.39
    175 schema:familyName Böning
    176 schema:givenName D.
    177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0773653551.22
    178 rdf:type schema:Person
    179 sg:pub.10.1007/bf00630281 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007891280
    180 https://doi.org/10.1007/bf00630281
    181 rdf:type schema:CreativeWork
    182 sg:pub.10.1007/bf01062394 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025280421
    183 https://doi.org/10.1007/bf01062394
    184 rdf:type schema:CreativeWork
    185 grid-institutes:None schema:alternateName Institute of Heart Surgery, Ludwigshafen, Germany, DE
    186 schema:name Institute of Heart Surgery, Ludwigshafen, Germany, DE
    187 rdf:type schema:Organization
    188 grid-institutes:grid.14095.39 schema:alternateName Institute of Sports Medicine, Universitätsklinikum Benjamin Franklin, Free University Berlin, Clayallee 229, D-14195 Berlin, Germany e-mail: gstrobel@zedat.fu-berlin.de Tel.: +49-30-81812573; Fax: +49-30-81812572, DE
    189 schema:name Institute of Sports Medicine, Universitätsklinikum Benjamin Franklin, Free University Berlin, Clayallee 229, D-14195 Berlin, Germany e-mail: gstrobel@zedat.fu-berlin.de Tel.: +49-30-81812573; Fax: +49-30-81812572, DE
    190 rdf:type schema:Organization
    191 grid-institutes:grid.7700.0 schema:alternateName Institute of Heart Surgery, Ruprecht Karls University, Heidelberg, Germany, DE
    192 schema:name Institute of Heart Surgery, Ruprecht Karls University, Heidelberg, Germany, DE
    193 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...